Why is Nath Bio-Genes falling/rising?

Recent Price Movement and Market Performance

On 05-Dec, Nath Bio-Genes closed at ₹142.45, down by ₹3.4 or 2.33%, marking a continuation of a downward trend that has persisted over the last four trading sessions. During this period, the stock has lost nearly 9.84% in value, hitting a fresh 52-week low of ₹140.1 intraday. This decline is further accentuated by the stock’s underperformance against its sector, lagging by 3.08% on the day. The weighted average price indicates that a significant volume of shares traded closer to the day’s low, signalling selling pressure among investors.

Moreover, Nath Bio-Genes is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish sentiment prevailing in the market. Despite a surge in delivery volume on 04-Dec, which rose by nearly 250% compared to the five-day average, the increased participation has not translated into price support, indicating that selling interest may be outweighing buying demand.

Fundamental Weaknesses Weighing on Investor Confidence

While Nath Bio-Genes boasts a relatively attractive valuation, with a return on capital employed (ROCE) of 5.8% and an enterprise value to capital employed ratio of 0.5, these positives are overshadowed by its weak profitability metrics and subdued growth trajectory. The company’s operating profits have declined marginally at a compound annual growth rate (CAGR) of -0.21% over the past five years, signalling stagnation in core earnings capacity.

Return on equity (ROE) averages at a modest 6.31%, indicating limited efficiency in generating profits from shareholders’ funds. This low profitability is further reflected in the company’s recent quarterly results for September 2025, where profit after tax (PAT) fell by 16.1% to ₹0.93 crore. Additionally, interest expenses have surged by over 30% to ₹6.86 crore in the latest six-month period, exerting pressure on net earnings. The company’s cash and cash equivalents have also dwindled to a low ₹0.74 crore, raising concerns about liquidity and financial flexibility.

Persistent Underperformance Against Benchmarks

Nath Bio-Genes has consistently underperformed the broader market and its peers over multiple time horizons. Over the past year, the stock has delivered a negative return of 28.49%, starkly contrasting with the Sensex’s positive 4.83% gain. This underperformance extends to longer periods as well, with the stock falling 17.8% over three years while the Sensex surged 36.41%, and a dramatic 51.97% decline over five years against a 90.14% rise in the benchmark index.

Such sustained underperformance has likely contributed to waning institutional investor interest. Institutional holdings have decreased by 1.58% in the previous quarter, now constituting a mere 1.08% of the company’s equity. Given that institutional investors typically possess greater analytical resources, their reduced stake may reflect diminished confidence in the company’s prospects.

Conclusion: Why Nath Bio-Genes Is Falling

The decline in Nath Bio-Genes’ share price as of 05-Dec is primarily driven by a combination of weak financial fundamentals, disappointing recent earnings, and persistent underperformance relative to market benchmarks. Despite an attractive valuation on certain metrics, the company’s low profitability, rising interest costs, and shrinking cash reserves have eroded investor confidence. The stock’s failure to sustain momentum above key moving averages and the reduction in institutional ownership further compound the negative sentiment.

Investors should weigh these factors carefully, especially given the stock’s consistent losses over multiple time frames and its inability to keep pace with broader market gains. While the company’s profits have shown a modest increase of 3.5% over the past year, this has not been sufficient to offset the broader concerns surrounding its operational efficiency and financial health.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →